Collectively, this demonstrates that targeting FGFR1 and the Akt pathway is a very effective strategy to control proliferation of FGFR1-overexpressing EGFR-TKI-resistant NSCLC cells. The gene discussed is AKT1; the disease is non-small cell lung carcinoma.